BOK Financial Corporation

BOKF Financial Banks Regional

BOK Financial Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, down 2.78% from fiscal 2024. In the quarter to June 2026, revenue grew 3.20%, EPS grew 33.3%, free cash flow grew 1,441.5% and total debt fell 16.2%, each against the same quarter a year earlier. Dividend growth for ten consecutive years.

124.88 0.12 −0.10%
Market cap
$7.6B
P/E
11.8×
Fwd P/E
12.5×
Dividend yield
2.02%
F-score
8/9
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Analyst’s Commentary of BOK Financial Corporation (BOKF) Performance

Updated

BOK Financial Corporation (BOKF), a regional powerhouse centered in Tulsa, Oklahoma, has been navigating the ups and downs of the banking world like a pro over the past decade. As a retail investor, you might know it best for its focus on energy, commercial, and consumer banking in the South and Midwest. But let’s cut through the noise: this bank’s fundamentals show resilience amid chaos—like the 2020 COVID shock that hammered deposits and lending, or the 2023 regional banking scare with SVB’s collapse, which tested even sturdy players like BOKF. Revenue has surged lately, profitability holds steady, but predictions hint at a cooldown ahead. With the stock trading near analyst consensus right now, insiders quietly selling, and metrics pointing to solid value, is this a buy, hold, or trim? I’ll break it down step by step, correlating the numbers to real-world performance and future bets.

Revenue Trajectory: A Boom Followed by a Projected Pullback

Start with the top line, because revenue is the lifeblood for banks—it’s what fuels lending and fee income. BOKF’s revenue climbed steadily from $1.5 billion in 2016 to $2.2 billion by 2019, a compound annual growth rate (CAGR) of about 13% over those years, driven by organic expansion and higher interest rates boosting net interest income. Then came 2020’s pandemic dip to $2.11 billion (-5%), as loan deferrals and caution reigned. Recovery kicked in, but the real fireworks hit in 2023: revenue exploded to $3.13 billion, up 54% from 2022’s $2.03 billion. That jump to $3.47 billion in 2024 (another 11% gain) correlates directly with Fed rate hikes from 2022-2023, which supercharged margins on loans and securities.

Why does this matter? Revenue per employee skyrocketed from $425K in 2022 to $688K in 2024—a 62% leap—showing efficiency gains without massive headcount bloat (employees hovered around 4,800-5,000). But here’s the twist: analyst forecasts predict a sharp 2025 drop to $2.14 billion (-38% from 2024), then modest recovery to $2.27 billion in 2026 (+6%) and $2.39 billion in 2027 (+5%). This likely ties to expected rate cuts cooling net interest margins, plus softer energy sector lending (BOKF has exposure there, hit by oil volatility post-2022 Ukraine war). Revenue per share follows suit, peaking at $54.53 in 2024 before sliding to $33.76 in 2025. If history repeats the post-COVID rebound, this dip could be temporary, but it flags caution for growth chasers.

Profitability and Earnings: Steady Eddies in a Volatile Sea

Digging deeper, net income tells a steadier story—key because it’s what trickles to shareholders via dividends or buybacks. From $232 million in 2016, it peaked at $616 million in 2021 (+165% total growth), dipped during rate normalization, then stabilized around $520-530 million in 2022-2024. Forecasts brighten: $537 million in 2025 (+3% from 2024’s $524 million), $582 million in 2026 (+8%), and $609 million in 2027 (+5%). Earnings per share (EPS) mirrors this, rising from $6.19 in 2020 to $8.14 in 2024, with predictions hitting $10.25 by 2027—a 26% jump from 2024 levels.

EBT margins explain the resilience: they topped out at 41% in 2021 amid low provisions but slid to 19% in 2024 as gross margins cratered from 91% in 2022 to 59% (provisioning for potential loan losses?). ROE, a banker’s report card on equity efficiency, stayed impressive at 9-11% most years—beating the industry average of ~8%—thanks to disciplined cost control. ROA (return on assets) around 1% is par for banking, signaling no major asset bloat. Correlation here? Higher revenue didn’t fully flow to margins post-2023 banking jitters, but EPS growth outpaces revenue forecasts, hinting at share buybacks (shares outstanding fell from 70.8 million in 2019 to 63.7 million in 2024, -10%).

Cash flow’s wilder: operating cash swung negative in 2020-2021 (pandemic liquidity crunch), but 2024’s $1.43 billion op cash (+2,062% from 2023’s $66 million) and $1.28 billion FCF drove free cash per share to $20.14. Capex remains low (-$146 million in 2024), freeing cash for debt paydown. This ties to stock performance: during 2021’s cash drought, shares dipped (low $68), but 2024’s FCF boom pushed highs to $122.

Balance Sheet Strength: Debt Discipline Pays Off

BOKF’s balance sheet screams stability—a must for banks prone to runs. Total debt plunged from $13.2 billion in 2019 to $3.16 billion in 2024 (-76%), slashing net debt from positive $10 billion territory to a cash-rich -$3.2 billion. Shareholder equity grew steadily to $5.55 billion (+14% from 2023), boosting book value per share from $78 to $87 (+11%). PB ratio hovers at 1.2x lately, cheap versus historical 1.1-1.7x, meaning you’re buying assets near book.

Working capital’s negative (typical for banks, as deposits fund loans), but the 2023-2024 improvement from -$4.5 billion to -$9.3 billion? Wait, that’s deeper negative—likely more deposits chasing fewer loans amid high rates. Post-2023 crisis, BOKF avoided the fate of weaker peers by maintaining liquidity, correlating with stock highs of $106-$122 in 2023-2024 versus 2020 lows around $35.

Valuation Metrics: Trading at a Reasonable Premium

Valuations look inviting for value hunters. PE ratio expanded from 11x in 2020 to 13x in 2024, still below 20-year averages for regional banks, especially with EPS growth ahead. PS ratio compressed to 1.95x in 2024 from 3.7x peaks, reflecting revenue growth outpacing price. EV/Sales at 1.8x screams bargain post-2024 FCF surge. Historically, when PB dipped below 1x (like 2020’s 0.9x), shares bottomed and rebounded 200%+ by 2024 highs.

Stock price evolution tracks fundamentals tightly: from 2016 lows of $44 amid oil slumps, to $110+ highs in 2021 on vaccine hopes, then steady climbs to $122 in 2024 on rate tailwinds. Compared to S&P bank index, BOKF outperformed post-2023 by avoiding deposit outflows.

Insider Activity: Sells, No Buys—A Yellow Flag?

Insider transactions are sparse but telling: zero buys across 2025-2026 periods, only sells by one director (ID: 87c7bda5-7568-4554-9646-3a1e586a95f8). This insider offloaded 12,800 shares total—from 55,945 in May 2025 to 45,852 by Jan 2026—for $1.45 million proceeds. Holdings dropped 18%, at prices implying confidence in liquidity but not urgency to buy. No panic dumping, but absence of buys amid forecasts? It correlates with the projected revenue dip—insiders might see softer 2025 ahead.

Analyst Price Targets and Recent Performance

The stock closed recently at a level where the mean analyst target sits just about even—roughly flat upside potential. The high target implies around 19% room to run if revenue beats forecasts, while the low suggests 14% downside if margins compress further. Street sees modest growth aligning with EPS ramps, but not explosive.

Outlook: Hold with Upside Catalysts

Looking ahead, BOKF’s poised for steady 5-8% EPS growth through 2027, supported by buybacks and efficiency. Rate cuts could pinch margins short-term (echoing 2025 revenue drop), but diversification beyond energy (via acquisitions like in 2018-2019) and strong ROE position it well. Major tailwinds: normalizing energy loans post-2022 volatility, potential M&A in fragmented regionals. Risks? Prolonged recession hitting provisions, or insider sells signaling caution.

For everyday investors, BOKF offers bank-like stability without big-bank bureaucracy—trading at fair valuations with 10%+ ROE. If you’re diversified, it’s a solid hold; watch Q1 2025 earnings for revenue confirmation. Pair it with broader market bets, but don’t chase if rates crash margins. Fundamentals say resilient, not revolutionary—perfect for patient portfolios.

(Word count: 1,128)